Business Standard

Syringes and needles maker put trade margin cap of 75% after NPPA nudge

Pricing regulation on medical devices gains momentum

Pharma
Premium

Centre had a few months ago brought coronary stents and orthopaedic knee implants under price cap

Veena ManiSohini DasAneesh Phadnis New Delhi
About a year since the National Pharma Pricing Authority (NPPA) put a price cap on coronary stents, medical devices industry is making a slow move to self-regulation by capping trade margins. Syringes and needles makers have put a cap of 75 per cent on trade margins, effective Republic Day, to avoid the wrath of pharma pricing regulator. The NPPA put a price cap on coronary stents and orthopaedic implants last year. 

Also, it forced over 15 other device makers to finally put a maximum retail price on devices for the first time to avoid overcharging by hospitals. 

Vimal Khemka, who

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 31 2018 | 10:19 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com